3yr old WCC w/ pt Not Mykid
|
|
- Cory Hubbard
- 5 years ago
- Views:
Transcription
1 3yr old WCC w/ pt Not Mykid Obesity Webcast Department of Pediatrics, New York State, Department of Health 2 16 yr old WCC, Last Yr Obesity w/ BMI Pt WLF 16 yr old w/ Cough. 3 4 Stigma of Child Obesity Pseudotumor Cerebri Hypothalamic Inflammation The lot of fat children is a sad one. They are bashful and ashamed of their shapeless figures, yet unable to conceal them. Wherever they go they attract attention..obesity is a serious handicap in the social life of a child, even more so of a teenager. Obesity does not have the dignity of other diseases 5 Bruch H. Pediatric Annals:
2 Percentage of teen girls who report frequent weight teasing Consider Waist Circumference Measure at the superior iliac crest with tape parallel to floor Adults Woman 35 inches Men 40 inches Waist to Height ratio >0.5 Neumark-Sztainer. J Adolesc Health. 2009;44: Instructional Video from CDC circumference/circumference.htm Consider Waist Circumference Age (yr) Boys / 90 th & 95 th (cm) Girls / 90 th & 95 th (cm) Cook S, Auinger P, Huang TT. "Growth curves for cardio-metabolic risk factors in children and adolescents." The Journal of pediatrics Sep; 155(3):S6.e NOW Laboratory Testing BMI 85-94%ile Without Risk Factors Non-Fasting Lipid Profile Once 9-11yr and then 17-18yr BMI 85-94%ile Age 10 Years & Older With Risk Factors Non-Fasting Lipid Profile ALT and AST Blood Glucose/HgbA1C 10 NOW Laboratory Testing BMI 95%ile Age 10 Years & Older Non-Fasting Lipid Profile ALT and AST Every 2 Glucose/HgbA1C Years Other Tests as Indicated by Health Risks Yogi on life in an obese teen s arteries - It gets late early out there ABNORMAL BLOOD GLUCOSE IN GENERAL PEDIATRICS
3 Summary of Issues in Pediatric Practice 1. Definitions Polling Question I am confident that I can identify the obese children who are at the highest risk of developing diabetes before they age out of my practice. Yes No 2. Predicting Type 2 Diabetes Risk Factors in the History Risk Factors on Physical Examination Screening Tests Who to test When to test 3. What type of diabetes is it? Type 1 can t wait Type 2 Diabetes Diagnostic Criteria 2010 Fasting Blood Glucose 126 mg/dl OR Casual Blood Glucose 200 mg/dl OR 2 hour OGTT sample 200 mg/dl OR HbA1c 6.5% If symptoms not present, need to have 2 abnormal samples Increased Risk for Diabetes Impaired Fasting Glucose mg/dl Abnormal Glucose Tolerance 2 hour glucose mg/dl on OGTT Borderline HbA1c HbA1c % Diabetes Care January 2010 vol. 33 no. Supplement 1 S11-S61 & S62-69 Diabetes Care January 2010 vol. 33 no. Supplement 1 S11-S61 & S62-69 Type 2 Diabetes A Two-Hit Disease Predicting Type 2 Diabetes High Insulin Production Low Type 2 Diabetes It s tough to make predictions; especially about the future. Low High Insulin Sensitivity 3
4 Identifying Those At Risk of T2DM Prenatal Environment Prenatal Exposure PAF* Maternal Diabetes 4.7% Maternal Obesity 19.7% Diabetes + Obesity 22.8% Total all Categories 47.2% Putative Predictors of T2DM in Children Odds Ratio IFG 8.2 HOMA-IR / Insulin 1.6 Insulin Calorie Intake 1.02 Metabolic Syndrome 11.5 Race 2.2 Parental History 5.0 Age at Follow-Up 1.1 *PAF Population Attributable Fraction Dabelea et al. Diab Care (2008) 31:1422. Morrison et al. Am J Clin Nut :778 Morrison et al. J Pediatr :201 Screening for Diabetes ADA Recommendations 2010 Screen Child for T2DM if 10 yrs old or at puberty BMI >85 th percentile PLUS Any 2 of Family History High Risk Race Insulin resistance* Maternal Diabetes or Gestational DM Re-check negatives every 3 years Associations With Insulin Resistance Acanthosis Nigricans Hypertension Dyslipidemia PCOS IUGR * Defined in next slide Diabetes Care January 2010 vol. 33 no. Supplement 1 S11-S61 & S (pg S17-S18) Diabetes Care January 2010 vol. 33 no. Supplement 1 S11-S61 & S (pg S17-S18) Incidence of Childhood Diabetes Type 1 vs Type 2 TODAY Study 1,206 children yo with type 2 diagnosis 118 (9.8%) autoantibody positive (GAD & IA-2) 71 single autoab 47 double autoab AutoAb-pos behaved like Type 1 over time The Writing Group for the SEARCH for Diabetes in Youth Study Group, JAMA 2007;297: If you come to a fork in the road, take it Klingensmith et al Diabetes Care Sept :
5 Steatosis (NAFL) 30% of adults 9% of children NAFLD: Quick Review Steatohepatitis (NASH) 3-5% of adults and children Why are we worried about NASH? NASH-related cirrhosis in the United States alone has increased 6 fold over the last decade. Now 3 rd leading cause for liver transplantation 2-12% of adults with NASH cirrhosis Cirrhosis Predicted to outpace all other etiologies for liver transplant in adults by Hepatocellular carcinoma 10-29% of adults with NASH within 10 years Afzali, A. Liver Transpl 2012;18(1):29-37 Fibrotic NASH can worsen significantly during adolescence Progression of fibrosis over 5 years Patient Initial Visit Follow Up Age (years) BMI 28 (97%ile) (99%ile) AST ALT GGT Patient lost to follow-up x 5 years BMI up 10 units RUQ tenderness Multiple abdominal striae Hepatomegaly 3cm below right costal margin Age 11 Age 16 Stage 1c fibrosis Stage 3 fibrosis Kohli R, anthakos SA et al. JPGN 2009 Kohli, anthakos et al. JPGN 2010 Kohli R, anthakos SA et al. JPGN 2009 Available Society Guidelines re: Screening overweight/obese children for NAFLD SOCIETY YES NO UNCERTAIN NOT STATED American Academy of Family Physicians American Academy of Pediatrics Does NAFLD fit criteria of screenable disease? Common? American Association for the Study of Liver Diseases High morbidity and mortality? American College of Gastroenterology American Gastroenterological Society Endocrine Society European Society for Pediatric GI, Hepatology and Nutrition National Association of Nurse Practitioners North American Society for Pediatric GI, Hepatology and Nutrition Accurate screening tool? Widely available therapy? +/- Schwimmer JB. Aliment Pharmacology & Therapeutics 2013;38:1267 5
6 Treatment Goals - Weight Loss Targets Age 2-5 Years BMI 85-94%ile BMI 85-94%ile BMI 95-98%ile No Risks With Risks Maintain weight Decrease weight Weight velocity velocity or maintenance weight maintenance Age 6-11 Years Maintain weight velocity Age Years Maintain weight velocity. After linear growth is complete, maintain weight 3yr old WCC w/ pt Not Mykid BMI >= 99%ile Gradual weight loss of up to 1 pound a month if BMI is very high (>21 or 22 kg/m2) Decrease weight velocity or weight maintenance Decrease weight velocity or weight maintenance Weight maintenance or gradual loss (1 lb per month) Weight loss (average is 2 pounds per week)* Weight loss (average is 2 pounds per week)* Weight loss (average is 2 pounds per week)* * Excessive weight loss should be evaluated for high risk behaviors 32 Pt MN Pt NW, first seen at 3yrs and noted to be obese PNP informed pt in Red zone as unhealthy. Can we discuss? 33 Pt WLF 16 yr old w/ Cough. 34 Pt WLF 16 yr old w/ Cough
7 16 yr old WCC, Last Yr Obesity w/ BMI 16 yr old WCC, Last Yr Obesity w/ BMI SUPPLEMENTAL SLIDES Diagnosis of NASH What is an abnormal ALT value? ALT Abnormal Values VARY WIDELY at children s hospitals (range >30-90 U/L) do not exclude overweight/obese or other causes of liver disease 95% percentile ALT for healthy weight, metabolically normal, teens in NHANES is: ALT 25.8 U/L for MALES ALT 22.1 U/L for FEMALES If ALT persistently > 2 x ULN (>50 U/L), more likely to have liver disease Limitations of ALT Cannot reliably differentiate NAFL from NASH Broad differential diagnosis if abnormal: need exclusionary testing ($$$) e.g. viral hepatitis, autoimmune, alpha 1 antitrypsin, hemochromatosis, Wilson disease Schwimmer JB. Gastroenterology 2010;138:1357 Schwimmer JB. Gastroenterology 2010;138:1357 Loomba R, Clin Gastro Hep 2008; 6(11):
8 Advanced Imaging: Transient Elastography Ultrasound limitations Transient Elastography- Fibroscan AUROC 0.99 for prediction of significant ( 2 fibrosis in Can evaluate liver structure/gall bladder Italian children with NAFLD, mean BMI 26, mean age 14) NO ROLE IN CONFIRMING OR DIAGNOSING NASH! Not reliable in identifying and measuring steatosis Cannot differentiate NAFL from NASH Marginean C. European Journal of Radiology 2012 (81): e870 Liver MRE Case Advanced Imaging: MRI Elastography (MRE) 4 yo with progressive intrahepatic cholestasis type 2 Mean liver stiffness 3.3 kpa = stage 2 fibrosis GE healthcare Images courtesy of Drs. Daniel Podberesky and Suraj Serai, Dept of Radiology, CCHMC Liver biopsy remains gold standard 35 children (majority NAFLD) with liver biopsy and MREL P=0.03 AUROC 0.92 (0.79,1.00) 88% sens, 85% specific at 2.71 kpa to detect fibrosis 2 PROS Can distinguish between NAFLD and NASH Clinical prognosis depends on histology NASH 25-30% risk of progression Early onset pediatric fibrosis more aggressive? Rule out other liver diseases (AIH, Wilson) Initiate more aggressive Rx and assess response CONS Fib 1 versus Fib 2 Risk 1:10,000 risk of death (in adults) Sampling error Expense anthakos et al; J Pediatr, 2014 Jan;164(1):
9 Pediatric NASH Treatment Recommendations 2012 ACG, AGA, AASLD Guidelines: Treatment of NASH Lifestyle modification always first step No medications recommended Metformin not recommended. Do not start Vitamin E More confirmatory studies needed 49 Severe NASH has been recommended as an indication for adolescent bariatric surgery, but supportive data still weak SELECTION CRITERIA FOR ADOLESCENT BARIATIC SURGERY BMI Comorbidities > 35 Type 2 DM moderate-severe OSA (AHI 15 events/hr) pseudotumor cerebri severe NASH > 40 Mild OSA (AHI>5 events/hr) HTN Insulin resistance/igt Dyslipidemia impaired QOL or ADL SUPPLEMENTAL SLIDES - DIABETES 52 Pratt, JSA et al. Obesity 2009; 17:901 Insulin Resistance (IR) & Acanthosis Nigricans Acanthosis Nigricans Sensitivity 0.48 ( ) Specificity 0.94 ( ) BMI 85 th percentile 0.74 ( ) 0.58 ( ) IR (by HOMA-IR>4) in 161 Native American Indians (aged 5-18 years) Acanthosis Nigricans in 15.1% of 5-11 yo and 30.9% of yo % overweight 25.8% (5-11) vs 19.1 (12-18) % obese 32.3 (5-11) vs 29.4 (12-18) BMI 95 th percentile About 80% of subjects with glucose intolerance had acanthosis Nigricans 0.57 ( ) 0.84 ( ) Nsiah-Kumi et al. J Natl Med Assoc. Oct :944 Clinical Screening for IGT 1004 overweight/obese German children 113 found to have pre-diabetes Correlation with pre-diabetes found with Parental diabetes history Pubertal Stage Extreme obesity (>99.5 % ile) 90% sensitivity if positive screen defined as: parental history OR Extreme obesity AND entered puberty No association with acanthosis Nigricans, waist circumference, hypertension, lipids, birth weight Reinehr et al. Pediatr Diabetes Sept :395. 9
10 What Does Fasting Insulin Tell Us? High insulin level (resistance) Does not predict diabetes in subjects without Fam Hx of T2DM High insulin is predictive when both of subject s parents have T2DM What Happens to Children with IGT? 128 German children with IGT 13.5 ± 2.1 years 53% female BMI = 31.7 ± FH- and 25FH+ developed T2DM during follow-up Goldfine et al: PNAS, : Kleber et al: Exp Clin Endocrinol Diabetes 2011; 119(3): Natural History of IGT in Children 3.9 yr F/U Normal Imp Gluc Toler Type 2 Diabet Lost to F/U N Higher 2-hour blood glucose, but not fasting blood glucose correlated with progression to T2DM and persistent IGT More subjects and longer follow-up is needed Kleber et al: Exp Clin Endocrinol Diabetes 2011; 119(3):
Disclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?
Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationMetabolic Syndrome Across the Life Cycle - Adolescent. Joy Friedman MD
Metabolic Syndrome Across the Life Cycle - Adolescent Joy Friedman MD Disclosures I have no actual or potential conflict of interest in relation to this program or presentation. I will mention off-label
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationType 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER
Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Yes! Is Type 2 diabetes the same in kids as in adults? And No!
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationChewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018
Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationCase Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010
Case Presentation Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010 Case HPI: 4 yo female with PMHx of obesity sent to ED from clinic with BS of 353. Pt. has had polyuria for the past
More informationDonna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico
Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationDistinguishing T1D vs. T2D in Childhood: a case report for discussion
Distinguishing T1D vs. T2D in Childhood: a case report for discussion Alba Morales, MD Associate Professor of Pediatrics Division of Pediatric Endocrinology and Diabetes Disclosure I have no financial
More informationEvaluating Obese Persons With Abnormal Liver Chemistries
Mary E. Rinella, MD, FAASLD Evaluating Obese Persons With Abnormal Liver Chemistries Postgraduate Course: Challenges in Management of Common Liver Diseases 275 1 25 year old obese Hispanic man with obesity,
More informationGestational Diabetes: Long Term Metabolic Consequences. Outline 5/27/2014
Gestational Diabetes: Long Term Metabolic Consequences Gladys (Sandy) Ramos, MD Associate Clinical Professor Maternal Fetal Medicine Outline Population rates of obesity and T2DM Obesity and metabolic syndrome
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationObesity Prevention and Treatment at Well Child Visits
Obesity Prevention and Treatment at Well Child Visits The Evidence-Based Approach to Clinical Care Susma Vaidya, MD Yolandra Hancock, MD Obesity Institute @ Children s National November 2, 2011 Today we
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationTimothy Fignar, MD FAAFP
Timothy Fignar, MD FAAFP Council for Obesity Related Education (CORE) speakers bureau for Takeda Pharmaceuticals Evaluate Health Risks Adjust Current Medications Recommend Caloric Intake Build Safe Exercise
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationAdolescent Bariatric Surgery
Adolescent Bariatric Surgery. Roundtable on Obesity Solutions - April 6, 2017 Marc Michalsky, M.D., FACS, FAAP Professor of Clinical Surgery and Pediatrics - The Ohio State University, College of Medicine
More informationEvaluation and Treatment of Childhood Obesity
Evaluation and Treatment of Childhood Obesity Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine and Children s Hospital Colorado In 1953, Morris et al compared
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationCardiometabolic Side Effects of Risperidone in Children with Autism
Cardiometabolic Side Effects of Risperidone in Children with Autism Susan J. Boorin, MSN, PMHNP-BC PhD Candidate Yale School of Nursing 1 This speaker has no conflicts of interest to disclose. 2 Boorin
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationUnderstand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients
Nicole Greenwood, M.D. Assistant Professor of Pediatrics LECOM Understand obesity/overweight definition Understand medical consequences How to better evaluate and manage obese/overweight pediatric patients
More information2010 ADA Guidelines: 1. Diagnostic Criteria for DM 2. Categories of increased risk of DM. Gerti Tashko, M.D. DM Journal Club 1/21/2010
2010 ADA Guidelines: 1. Diagnostic Criteria for DM 2. Categories of increased risk of DM Gerti Tashko, M.D. DM Journal Club 1/21/2010 NEW: Diagnosis with A1c 6.5% Cut point of A1c 6.5% diagnoses 33% less
More informationPrevention and Treatment of Pediatric Obesity and Diabetes
Prevention and Treatment of Pediatric Obesity and Diabetes Help Kids and Teens Get on a Healthy Track with the Good Health Club Physician Guidelines As you know, Americans weigh more each year. In fact,
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationLipoatrophic Diabetes: What can zebras teach us about horses? Ranganath Muniyappa, MD, PhD Diabetes, Endocrinology, and Obesity Branch NIDDK, NIH
Lipoatrophic Diabetes: What can zebras teach us about horses? Ranganath Muniyappa, MD, PhD Diabetes, Endocrinology, and Obesity Branch NIDDK, NIH Objectives 1. Describe the clinical manifestations of abnormal
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationDisclosures. Obesity and Its Challenges: Outline. Outline 5/2/2013. Lan Vu, MD Division of Pediatric Surgery Department of Surgery
Obesity and Its Challenges: Bariatric Surgery: Why or Why Not I have nothing to disclose Disclosures Lan Vu, MD Division of Pediatric Surgery Department of Surgery Outline Growing obesity epidemic Not
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationDISCLOSURES: 8/27/18 USE OF A SHARED MEDICAL APPOINTMENT FOR PEDIATRIC OBESITY
DISCLOSURES: Nothing to disclose USE OF A SHARED MEDICAL APPOINTMENT FOR PEDIATRIC OBESITY Catherine Lux, DNP,RN,CPNP-PC https://encrypted-tbn0.gstatic.com/images?q=tbn:and9gcrafxzs7e6tfxm2vxdjdp9fmkun25ryuuyqimh2f4zgg2df_gs_sq
More informationFollow-up of pediatric chronic liver disease
IV CONVEGNO ITALO-BRASILIANO DI PEDIATRIA E NEONATOLOGIA SALVADOR DE BAHIA 21-23 MARZO 2006 Follow-up of pediatric chronic liver disease Antonio Colecchia, Luca Laudizi Dpt of Internal Medicine and Gastroenterology
More informationLiver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
More informationAutoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
More informationEffective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.
Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
More informationPREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS
PREVALENCE OF METABOLİC SYNDROME İN CHİLDREN AND ADOLESCENTS Mehmet Emre Atabek,MD,PhD Necmettin Erbakan University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology and
More informationTreating Severe Obesity in Children: Non-Surgical Approaches
Treating Severe Obesity in Children: Non-Surgical Approaches Pediatric Comprehensive Weight Management Center Susan J. Woolford, MD, MPH National Academies of Sciences Workshop - Roundtable on Obesity
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More information6/28/2017. Update in NAFLD. Key Points. NAFLD: Epidemiology. US Population: million. NALFD Prevalence 25% 80 million
Update in NAFLD PHILLIP K HENDERSON, DO ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE INSTRUCTOR OF SURGERY, DIVISION OF TRANSPLANT SURGERY UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationDiagnostic Test of Fat Location Indices and BMI for Detecting Markers of Metabolic Syndrome in Children
Diagnostic Test of Fat Location Indices and BMI for Detecting Markers of Metabolic Syndrome in Children Adegboye ARA; Andersen LB; Froberg K; Heitmann BL Postdoctoral researcher, Copenhagen, Denmark Research
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationInsulin Sensitivity and Secretion in Youth: From Normal to Diabetes
Insulin Sensitivity and Secretion in Youth: From Normal to Diabetes Silva A. Arslanian MD Richard L. Day Professor of Pediatrics 1 year Jubilee, The Queen Silvia Children s Hospital Gothenburg, Sweden
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationChildhood Obesity and Type II Diabetes: A Rising Epidemic
Childhood Obesity and Type II Diabetes: A Rising Epidemic Charli Oquin, MS, APRN, PNP, NCSN, CNA Presentation Texas Association of Perianesthesia Nurses (TAPAN) September, 2010 National Initiatives Addressing
More informationAdolescent Obesity GOALS BODY MASS INDEX (BMI)
Adolescent Obesity GOALS Lynette Leighton, MS, MD Department of Family and Community Medicine University of California, San Francisco December 3, 2012 1. Be familiar with updated obesity trends for adolescent
More informationNONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH
NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute
More information